Recombinant Human Coagulation Factor Vila in Jehovah's Witness Patients Undergoing Liver Transplantation

Jabbour, Nicolas; Gagandeep, Singh; Cheng, Peilin Alice; Boland, Brendan; Mateo, Rod; Genyk, Yuri; Selby, Rick; Zeger, Gary
February 2005
American Surgeon;Feb2005, Vol. 71 Issue 2, p175
Academic Journal
Indisputably, liver transplantation is among the most technically challenging operations in current practice and is compounded by significant coagulopathy and portal hypertension. Recombinant human coagulation factor Vila (rFVIIa) is a new product that was initially described to treat bleeding in hemophilia patients. We present in this paper 10 liver transplants in Jehovah's Witness patients using this novel product at University of Southern California-University Hospital. The subject population included nine males and one female with an average age of 50 years. Six patients underwent cadaveric and four live donor liver transplantation. Surgeries were conducted following our established protocol for transfusion-free liver transplantation, which includes preoperative blood augmentation, intraoperative blood salvage, acute normovolemic hemodilution, and postoperative blood conservation. Factor (rFVIIa) was used at a dose of 80 µg/kg intravenously just prior to the incision in all patients, and a second intraoperative dose was used in 3 patients. All living donor liver transplantation (LDLT) recipients did well and were discharged uneventfully with normal liver functions. Two of the six cadaveric recipients died. One patient died intraoperatively from acute primary graft nonfunction, and the other died 38 hours postoperatively from severe anemia. This report suggests factor rFVIIa might have a much broader application in surgery in the control of bleeding associated with coagulopathy.


Related Articles

  • A chamber of hope for hemophilia. Pipe, Steven W.; Kaufman, Randal J. // Nature Biotechnology;Mar2000, Vol. 18 Issue 3, p264 

    Focuses on the blood coagulation disorder hemophilia. Cause of the disease; Role of genetic engineering in treating hemophiliacs; Side effects of the treatment; Method devised by Ton-That and coworkers to overcome the obstacles.

  • Hemophilia bypassed. DeWitt, Natalie // Nature Biotechnology;Mar2000, Vol. 18 Issue 3, p251 

    Focuses on the blood coagulation disorder hemophilia, caused by deficiencies or defects of blood coagulation factors. Side effects of therapies based on replacement of defective plasma proteins; Limitations of using recombinant Factor VIIa in the treatment of the disease; Development of an...

  • Further assessment for factor VIII meds recommended by PRAC.  // Reactions Weekly;Nov2014, Vol. 1528 Issue 1, p5 

    The article reports that according to the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency, patients with previously untreated haemophilia may be at greater risk of developing inhibitors if treated with the second-generation factor VIII products.

  • Use of desmopressin and erythropoietin in an anaemic Jehovah's Witness patient with severely impaired coagulation capacity undergoing stentless aortic valve replacement. Beholz, S.; Liu, J.; Thoelke, R.; Spiess, C.; Konertz, W. // Perfusion;Nov2001, Vol. 16 Issue 6, p485 

    Cardiac surgery in Jehovah's Witness patients remains a challenge in the presence of concomitant congenital or acquired coagulation disorders and anaemia. We report a case of a 66-year-old female Jehovah's Witness suffering from severe calcified aortic valve stenosis requiring aortic valve...

  • Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Björkman, S.; Berntorp, E.; Björkman, S // Clinical Pharmacokinetics;2001, Vol. 40 Issue 11, p815 

    Haemophilia is a recessively inherited coagulation disorder, in which an X-chromosome mutation causes a deficiency of either coagulation factor VIII (FVIII) in haemophilia A, or factor IX (FIX) in haemophilia B. Intravenous administration of FVIII or FIX can be used to control a bleeding...

  • The laboratory diagnosis of the carrier state for classic hemophilia. Ratnoff, Oscar D.; Jones, Paul K.; Ratnoff, O D; Jones, P K // Annals of Internal Medicine;May77, Vol. 86 Issue 5, p521 

    Estimation of the titer of procoagulant antihemophilic factor (AHF) and the concentration of AHF-like antigens, as detected by heterologous antiserum, provides a method for diagnosis of the carrier state of classic hemophilia. Among 87 obligate carriers, 82, or 94%, could be identified as...

  • Useful websites relating to haemophilia treatment. Barnard, Keith // GP: General Practitioner;4/27/2007, p32 

    The article presents information on several web sites that offers information about hemophilia. The website www.ukhcdo.org/ offers a list of all the hemophilia centers in Great Britain. The website www.haemophilia.org.uk/ offers patient information on hemophilia. The website...

  • Clinical and Genetic Aspects of Coagulopathies. Koller, Fritz // Annals of Internal Medicine;Apr65, Vol. 62 Issue 4, p744 

    Focuses on the clinical and genetic aspects of blood coagulation disorders. Deficiency of clotting factors in hereditary and acquired coagulopathies; Hemophilia in royal families in Europe; Potentiation of anticoagulant effect of dicoumarol derivative by phenylbutazone.

  • Acquired Inhibitor of Blood Coagulation. Lee, Martin L.; Raccuglia, Giovanni // Annals of Internal Medicine;Jun62, Vol. 56 Issue 6, p946 

    Describes the studies carried out in a patient affected by a hemorrhagic diathesis which was produced by a blood clotting effect. Abnormal thromboplastin formation and inhibition of thrombin activity; Altered coagulation mechanism; Therapy.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics